Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF
  • Original article
  • Open access
  • Published:

Relation of ischemia-modified albumin to disease manifestations and activity in Egyptian patients with Behçet’s disease

Egyptian Rheumatology and Rehabilitation volume 46, pages 108–112 (2019)Cite this article

Abstract

Aim of work

To determine level of ischemia-modified albumin (IMA) in patients with Behçet’s disease (BD) and to assess its role in disease manifestations and activity.

Patients and methods

The study included 48 patients with BD and 38 matched controls. Disease activity was estimated by the BD current activity form. Serum IMA was measured.

Results

Mean age of the patients was 33.8±7.9 years. There were 42 males and six females, and the disease duration was 52.9±48.8 months. The serum IMA level was significantly increased in the patients with BD (50.9±12.9 U/ml) compared with the control (7.76±1.6 U/ml) (P<0.001). There was a statistically significant association between IMA level and disease activity, with high mean IMA level among active cases (P=0.01). There was no statistically significant association between IMA level and any of other clinical characteristics in patients with BD. Sensitivity and specificity test for IMA level in detection of cases illustrated accuracy of 98.5% with sensitivity 95.8% and specificity 78.9% at cutoff value of 9.4 U/ml.

Conclusion

There is growing evidence indicating the role of oxidative stress in BD. IMA is accepted as an essential marker of oxidative stress in patients with BD. It has a potential diagnostic value for the detection of the disease. Furthermore, it correlates with the disease activity.

References

  1. Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, et al. Population based prevalence study of Behcet’s disease differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58:3951–3959.

    Article  Google Scholar 

  2. Khabbazi A, Rashtchizadeh N, Ghorbanihaghjo A, Hajialiloo M, Ghojazadeh M, Taei R, Kolahi S. The status of serum vitamin D in patients with active Behcet’s disease compared with controls. Int J Rheum Dis 2014; 17:430–434.

    Article  CAS  Google Scholar 

  3. Gheita TA, Raafat H, Khalil H, Hussein Serum H. Level of APRIL/BLyS in Behçet’s disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol 2013; 23:542–546.

    Article  CAS  Google Scholar 

  4. Gheita TA, Gamal SM, Shaker I, El Fishawy HS, El Sisi R, Shaker OG, et al. Clinical significance of serum interleukin-23 and A/G gene (rs17375018) polymorphism in Behçets disease: relation to neuro-Behçet, uveitis and disease activity. Joint Bone Spine 2015; 82:213–215.

    Article  CAS  Google Scholar 

  5. Taysi S, Kocer I, Memisogullari R, Kiziltunc A. Serum oxidant/antioxidant status in patients with Behçet’s disease. Ann Clin Lab Sci 2002; 32:377–382.

    CAS  PubMed  Google Scholar 

  6. Behera S, Mangaraj M, Mohapatra PC. Diagnostic efficacy of ischemia modified albumin and its correlation with lipid profile, oxidative stress in acute myocardial infarct patients on admission. Asian Pac J Trop Dis 2012; 2:62–65.

    Article  CAS  Google Scholar 

  7. Jena I, Mohapatra PC, Mohanty NR. Ischemia modified albumin: a biochemical marker of acute stroke. Int J Pharm Bio Sci 2016; 7:15–19.

    CAS  Google Scholar 

  8. Gunduz A, Turedi S, Mentese A, Karahan SC, Hos G, Tatli O, et al. Ischemia-modified albumin in the diagnosis of acute mesenteric ischemia: a preliminary study. Am J Emerg Med 2008; 26: 202–205.

    Article  Google Scholar 

  9. Ozdemir M, Kivici A, Balevi A, Mevlitoğlu I, Peru C. Assessment of ischaemia-modified albumin level in patients with psoriasis. Clin Exp Dermatol 2012; 37:610–614.

    Article  CAS  Google Scholar 

  10. Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28:338–347.

    Article  Google Scholar 

  11. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38:728–733.

    Article  CAS  Google Scholar 

  12. Emmi G, Silvestri E, Squatrito D, Amedei A, Niccolai E, D’Elios MM, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J 2015; 13:15.

    Article  Google Scholar 

  13. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto-oxidative damage in Behcet’s disease endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982; 49:247–255.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet’s syndrome. J Am Coll Cardiol 2001; 37:517–520.

    Article  CAS  Google Scholar 

  15. Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status in serum of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002; 40:684–688.

    CAS  PubMed  Google Scholar 

  16. Karkucak M, Capkin E, Alver A, Akyuz A, Kiris A, Ak E, et al. The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. Clin Rheum 2010; 29:303–307.

    Article  Google Scholar 

  17. Aydin O, Ellidag HY, Eren E, Kurtulus F, Yaman A, Yılmaz N. Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochem Med (Zagreb) 2014; 24:383–389.

    Article  Google Scholar 

  18. Capkin E, Karkucak M, Kola M, Karaca A, Aydin Capkin A, Caner Karahan S. Ischemia-modified albumin (IMA): a novel marker of vascular involvement in Behçet’s disease? Joint Bone Spine 2015; 82:68–69.

    Article  CAS  Google Scholar 

  19. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: An endogenous response to ischemia? Int J Cardiol 2006; 108:410–411.

    Article  Google Scholar 

  20. Ozyazgan S, Andican G, Erman H, Tuzcu A, Uzun H, Onal B, Ozyazgan Y. Relation of protein oxidation parameters and disease activity in patients with Behçet’s disease. Clin Lab 2013; 59:819–825.

    Article  CAS  Google Scholar 

  21. Eom JE, Lee E, Jeon KH, Sim J, Suh M, Jhon GJ, et al. Development of an albumin copper binding (ACuB) assay to detect ischemia modified albumin. Anal Sci 2014; 30:985–990.

    Article  CAS  Google Scholar 

  22. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006; 92:113–114.

    Article  CAS  Google Scholar 

  23. Kılıç S, Isık S, Hiz MM, Çakır DÜ, Türkön H, Cevizci S, Ogretmen Z. The ischemia modified albumin and mean platelet volume levels in patients with Behçet’s disease. Postepy Dermatol Alergol 2016; 33:345–348.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Rheumatology and Rehabilitation, Faculty of Medicine, Fayoum University, Fayoum, 63511, Egypt

    Nermeen A. Fouad MD

  2. Departments of Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt

    Tarek I. Ahmed

  3. Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt

    Olfat G. Shaker

  4. Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Fayoum University, Fayoum, Egypt

    Omayma O. Abdelaleem

Authors
  1. Nermeen A. Fouad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tarek I. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olfat G. Shaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Omayma O. Abdelaleem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nermeen A. Fouad MD.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fouad, N.A., Ahmed, T.I., Shaker, O.G. et al. Relation of ischemia-modified albumin to disease manifestations and activity in Egyptian patients with Behçet’s disease. Egypt Rheumatol Rehabil 46, 108–112 (2019). https://doi.org/10.4103/err.err_66_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/err.err_66_18

Keywords